CONFIDENTIAL — APPROVED FOR PUBLIC RELEASE · BUREAU FILE COPY RECORDS CURRENT AS OF 29 MAY 2026 · DISTRIBUTION: UNRESTRICTED
VendorInvestigator Independent Testing Bureau · Public Records Division
DOCKET YEAR 2026 · VOL. II
35,156 SAMPLES ON FILE
No fee · No favor
Compound Evidence File
#EC-2026-0239

Stanozolol (Winstrol) Raw

Filed under Raw Materials. The bureau holds 123 laboratory returns for this compound from 40 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.

Cross-Index

Subjects Shipping This Compound

40 SUBJECTS
SubjectGradeSamplesMeanMinMaxFirst seenLast seen
WuXi TIDESCASE #VI-2026-0335 A 5 10.0 9.9 10.0 10 Nov 2025 23 Jul 2026
Tianjin Finder Chemical TFCCASE #VI-2026-0693 A 4 10.0 9.9 10.0 14 Nov 2025 16 Apr 2026
Shanghai Sigma AudleyCASE #VI-2026-0505 A 4 10.0 10.0 10.0 8 Mar 2026 8 Jul 2026
Sangon BioCASE #VI-2026-0671 A 3 10.0 9.9 10.0 16 Feb 2026 6 Jun 2026
Kerui PeptidesCASE #VI-2026-0626 A 3 10.0 9.9 10.0 28 May 2026 9 Jul 2026
Mokemei BiotechnologyCASE #VI-2026-0540 A 3 10.0 10.0 10.0 5 Mar 2026 8 Jul 2026
Shanghai Wibson BiotechnologyCASE #VI-2026-0379 A 3 10.0 10.0 10.0 24 Jan 2026 11 Jul 2026
Chinese Peptide CompanyCASE #VI-2026-0184 A 3 10.0 9.9 10.0 19 Dec 2025 28 May 2026
GenScript PeptidesCASE #VI-2026-0860 A 3 10.0 9.9 10.0 18 Apr 2026 25 Jun 2026
HomopeptideCASE #VI-2026-0760 A 7 9.9 9.9 10.0 24 May 2026 24 May 2026
QYAOBIOCASE #VI-2026-0861 A 4 9.9 9.9 10.0 14 Nov 2025 8 Jul 2026
Hubei JianxiangCASE #VI-2026-0048 A 4 9.9 9.9 10.0 13 Mar 2026 12 Jul 2026
Flourishglobal PeptideCASE #VI-2026-0630 A 4 9.9 9.9 10.0 13 Nov 2025 15 Apr 2026
PolyPeptide GroupCASE #VI-2026-0143 A 4 9.9 9.9 10.0 11 Apr 2026 14 Aug 2026
SinoPepCASE #VI-2026-0387 A 4 9.9 9.9 10.0 6 Feb 2026 25 Jul 2026
AsymchemCASE #VI-2026-0091 A 3 9.9 9.9 10.0 11 Mar 2026 4 Jul 2026
AmbioPharmCASE #VI-2026-0177 A 3 9.9 9.9 10.0 2 May 2026 17 Jul 2026
Shanghai ERP BiotechnologyCASE #VI-2026-0936 A 2 9.9 9.9 9.9 8 May 2026 21 Jun 2026
JEEP PeptidesCASE #VI-2026-0457 A 2 9.9 9.9 10.0 23 Feb 2026 23 May 2026
BachemCASE #VI-2026-0314 A 2 9.9 9.9 10.0 20 Jan 2026 9 Mar 2026
Hybio PharmaceuticalCASE #VI-2026-0065 A 2 9.9 9.9 9.9 2 Aug 2026 4 Aug 2026
Sigma-AldrichCASE #VI-2026-0829 A 2 9.9 9.9 10.0 16 Dec 2025 8 Jul 2026
Thermo Fisher ScientificCASE #VI-2026-0142 A 2 9.9 9.9 10.0 7 Apr 2026 2 Jul 2026
Huaian Hanyou PeptideCASE #VI-2026-0297 X 1 9.4 9.4 9.4 27 Feb 2025 27 Feb 2025
Orbitrex PeptidesCASE #VI-2026-0812 X 1 9.1 9.1 9.1 8 Jul 2025 8 Jul 2025
Qingdao Sigma Chemical QSCCASE #VI-2026-0538 A 3 8.9 7.8 10.0 21 May 2026 21 May 2026
Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 A 5 8.4 6.1 9.4 23 May 2026 23 May 2026
Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 A 2 8.4 7.9 8.8 24 May 2026 24 May 2026
Glbiochem (Shanghai)CASE #VI-2026-0704 A 7 8.0 6.5 9.3 24 May 2026 24 May 2026
Shanghai Sigma Audley SSACASE #VI-2026-0486 A 5 8.0 7.1 9.7 23 May 2026 23 May 2026
Top PeptideCASE #VI-2026-0721 X 1 8.0 8.0 8.0 16 Mar 2025 16 Mar 2025
Polaris PeptidesCASE #VI-2026-0839 X 4 7.3 6.5 8.8 14 Jan 2025 17 May 2026
SRY LabsCASE #VI-2026-0657 X 9 7.1 4.5 8.7 3 Jul 2025 23 May 2026
Risynth BioCASE #VI-2026-0672 X 1 7.1 7.1 7.1 11 Jun 2025 11 Jun 2025
Reta-PeptideCASE #VI-2026-0756 X 3 6.4 5.1 7.8 2 Apr 2025 20 May 2026
Haikou Mingheng BiotechnologyCASE #VI-2026-0126 X 1 6.4 6.4 6.4 28 Mar 2025 28 Mar 2025
Huayi BiotechnologyCASE #VI-2026-0243 X 1 5.9 5.9 5.9 16 Mar 2025 16 Mar 2025
Peptides For SaleCASE #VI-2026-0614 X 1 3.3 3.3 3.3 8 Jul 2025 8 Jul 2025
PRIVATECASE #VI-2026-0635 X 1 0.0 0.0 0.0 11 Jun 2025 11 Jun 2025
Guangzhou Yuao TradingCASE #VI-2026-0787 X 1 0.0 0.0 0.0 14 Jan 2025 14 Jan 2025

Open any subject to view the batch-level evidence for Stanozolol (Winstrol) Raw alone.